Cancer Cell Research

Cancer Cell Research is an open access journal dedicated to publishing findings resulting from conferences, workshops, and similar events, in all areas of chemistry. The conference organizers and proceedings editors are responsible for managing the peer-review process and selecting papers for conference proceedings.
    Online ISSN: 2161-2609     About Open Access Journals

Vol. 11

NO.41 2024

Vol. 11

NO.42 2024

Vol. 11

NO.43 2024

Vol. 11

NO.44 2024
Article
Advances in glioma ecDNA research
Cancercellresearch 2023, 9(36), 897-902; - 25 Mar. 2023
Abstract
: Glioma is the most common primary tumor of the central nervous system and the tumor genetics of glioma has been a hot topic. In recent years, the role of ecDNA in tumors, especially glioma, has been gradually recognized. [...] Read more.
: Glioma is the most common primary tumor of the central nervous system and the tumor genetics of glioma has been a hot topic. In recent years, the role of ecDNA in tumors, especially glioma, has been gradually recognized. ecDNA can accelerate tumor evolution and mediate glioma drug resistance activity by randomly distributing in the interphase due to the lack of mitotic structure. The circle structure of ecDNA also has the characteristics of high openness, strong transcriptional activity and diverse regulatory modes. The study of glioma ecDNA has gone through three stages: classical karyotype analysis, basic function study and regulatory molecular mechanism study. In the era of karyotype analysis, early studies focused mostly on the description of cell karyotypes, but later merged with research on oncogenes. In the era of functional study of ecDNA, not only have many oncogenes located on ecDNA had been discovered, but also the mechanism of ecDNA involvement in glioma drug resistance had been revealed. In the past five years, the finer molecular regulatory mechanisms have become essential in further revealing the unique functions of ecDNA, mainly due to the advancement of biology experiments research tools and bioinformatics technologies. Full article
(This article belongs to the Section Cancer cell Research)
Article
Research Progress of TMB in Predicting Prognosis and Efficacy of Lung Cancer
by , .
Cancercellresearch 2023, 9(36), 891-896; -28 Feb. 2023
Abstract
: Immune checkpoint inhibitors (ICIs) have changed therapeutic paradigms for patients across multiple cancer types and play an important role. However, due to the complexity and individual differences in immunotherapy, not all patients benefit from immunotherapy. New insights into the role of tumor mutational burden (TMB) suggest that their composition, as well as their functionality, might serve as a biomarker to enable optimal patient selection for current systemic therapies and upcoming treatment options. [...] Read more.
: Immune checkpoint inhibitors (ICIs) have changed therapeutic paradigms for patients across multiple cancer types and play an important role. However, due to the complexity and individual differences in immunotherapy, not all patients benefit from immunotherapy. New insights into the role of tumor mutational burden (TMB) suggest that their composition, as well as their functionality, might serve as a biomarker to enable optimal patient selection for current systemic therapies and upcoming treatment options. In this paper, we will review TMB as a biomarker for immunotherapy, assess the efficacy of immunotherapy, present several combinations of biomarkers to improve treatment prediction, and further evaluate the limitations of TMB as a biomarker of immunotherapy for lung cancer. Full article
(This article belongs to the Section cancercellresearch)
Back to TopTop